CU20170172A7 - 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos - Google Patents

4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos

Info

Publication number: CU20170172A7
Authority: CU; Cuba
Prior art keywords: diaminoquinolin; analgesic; carbonitrils; antipirétic; antineoplásicos
Prior art date: 2015-07-06

Application number

CUP2017000172A

Other languages

English (en)

Spanish (es)

Inventor

Elizabeth Bacon

Gayatri Balan

Chien-Hung Chou

Christopher Clark

Jeromy J Cottell

Musong Kim

Thorsten A Kirschberg

John O Link

Gary Phillips

Scott D Schroeder

Neil H Squieres

Kirk L Stevens

James G Taylor

William J Watkins

Nathan E Wright

Sheila M Zipfel

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-06

Filing date

2016-06-30

Publication date

2018-06-05

2016-06-30 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2018-06-05 Publication of CU20170172A7 publication Critical patent/CU20170172A7/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Obesity (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)

CUP2017000172A 2015-07-06 2016-06-30 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos CU20170172A7 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562189158P	2015-07-06	2015-07-06
US201562269060P	2015-12-17	2015-12-17
PCT/US2016/040520 WO2017007689A1 (en)	2015-07-06	2016-06-30	Cot modulators and methods of use thereof

Publications (1)

Publication Number	Publication Date
CU20170172A7 true CU20170172A7 (es)	2018-06-05

Family

ID=56411943

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CUP2017000172A CU20170172A7 (es)	2015-07-06	2016-06-30	4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos

Country Status (41)

Country	Link
US (7)	US20170008905A1 (ar)
EP (3)	EP3896064A1 (ar)
JP (6)	JP6430060B2 (ar)
KR (5)	KR20220129667A (ar)
CN (4)	CN114380799B (ar)
AU (5)	AU2016290820B2 (ar)
BR (1)	BR102016015656B1 (ar)
CA (1)	CA2971640C (ar)
CL (1)	CL2017003356A1 (ar)
CO (1)	CO2017013351A2 (ar)
CR (1)	CR20170599A (ar)
CU (1)	CU20170172A7 (ar)
CY (1)	CY1121750T1 (ar)
DK (1)	DK3191470T3 (ar)
DO (1)	DOP2017000311A (ar)
EA (1)	EA036788B1 (ar)
EC (1)	ECSP17084635A (ar)
ES (2)	ES2734713T3 (ar)
HR (1)	HRP20190853T1 (ar)
HU (1)	HUE043310T2 (ar)
IL (4)	IL293770B2 (ar)
LT (1)	LT3191470T (ar)
MA (1)	MA39422B1 (ar)
ME (1)	ME03425B (ar)
MX (1)	MX370984B (ar)
MY (1)	MY196173A (ar)
NZ (2)	NZ738525A (ar)
PE (1)	PE20180462A1 (ar)
PH (2)	PH12018500031B1 (ar)
PL (2)	PL3191470T3 (ar)
PT (2)	PT3191470T (ar)
RS (1)	RS58639B1 (ar)
SA (1)	SA517381350B1 (ar)
SG (1)	SG11201702041PA (ar)
SI (2)	SI3456717T1 (ar)
SM (1)	SMT201900244T1 (ar)
SV (1)	SV2017005605A (ar)
TW (3)	TWI748539B (ar)
UA (1)	UA123010C2 (ar)
UY (1)	UY36771A (ar)
WO (1)	WO2017007689A1 (ar)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9540343B2 (en)	2011-07-06	2017-01-10	Gilead Sciences, Inc.	Compounds for the treatment of HIV
US10118890B2 (en)	2014-10-10	2018-11-06	The Research Foundation For The State University Of New York	Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
US9815818B2 (en)	2015-07-06	2017-11-14	Gilead Sciences, Inc.	Cot modulators and methods of use thereof
UA123010C2 (uk)	2015-07-06	2021-02-03	Гіліад Сайєнсіз, Інк.	Модулятори сот та способи їх застосування
EP3478674B1 (en)	2016-06-30	2020-05-13	Gilead Sciences, Inc.	4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN109890808B (zh) *	2016-08-19	2020-08-07	吉利德科学公司	用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
EA036921B1 (ru) *	2017-02-10	2021-01-15	Джилид Сайэнс, Инк.	Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
CN108794516A (zh) *	2017-04-26	2018-11-13	上海时莱生物技术有限公司	硼酸和硼酸酯类化合物及其制备方法和用途
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
AR112413A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas sólidas de un inhibidor de la cápside del vih
EP3689866A4 (en) *	2017-09-26	2021-07-07	Nippon Soda Co., Ltd.	QUINOLINE COMPOUND AND BACTERICIDAL AGENT FOR AGRICULTURE AND HORTICULTURE
PL3752495T3 (pl)	2018-02-15	2024-01-15	Gilead Sciences, Inc.	Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
JP7038843B2 (ja)	2018-02-16	2022-03-18	ギリアードサイエンシーズ，インコーポレイテッド	Ｒｅｔｒｏｖｉｒｉｄａｅウイルス感染の処置において有用な治療用化合物を調製するための方法および中間体
US11760701B2 (en)	2018-02-27	2023-09-19	The Research Foundation For The State University Of New Yrok	Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same
CN110294660B (zh) *	2018-03-23	2021-09-24	中国农业大学	一种含碳碳三键和/或碳氮三键的不饱和有机化合物的还原氘化方法
CN108658996A (zh) *	2018-06-25	2018-10-16	中国药科大学	一种氘代Fiduxosin的制备方法
US11944611B2 (en)	2018-07-16	2024-04-02	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of HIV
TW202235416A (zh) *	2019-06-14	2022-09-16	美商基利科學股份有限公司	Cot 調節劑及其使用方法
MX2022002339A (es)	2019-08-29	2022-04-06	Idorsia Pharmaceuticals Ltd	Derivados de alfa-d-galactopiranosido.
EP4065116A1 (en)	2019-11-26	2022-10-05	Gilead Sciences, Inc.	Capsid inhibitors for the prevention of hiv
JP2023520650A (ja) *	2020-03-30	2023-05-18	ギリアードサイエンシーズ，インコーポレイテッド	（Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
CN119390681A (zh) *	2020-04-02	2025-02-07	吉利德科学公司	用于制备cot抑制剂化合物的方法
TW202502766A (zh)	2020-06-25	2025-01-16	美商基利科學股份有限公司	用於治療hiv之蛋白殼抑制劑
MX2023010241A (es)	2021-03-03	2023-09-12	Idorsia Pharmaceuticals Ltd	Derivados de alfa-d-galatopiranosido triazolil-metil sustituidos.
TW202345826A (zh)	2021-06-04	2023-12-01	美商基利科學股份有限公司	治療nash之方法
US20240285646A1 (en) *	2021-06-11	2024-08-29	Neuronascent, Inc.	Methods and compositions for lipid formulation of lipophilic small molecule therapies of the heterocyclic type
TW202342448A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
JP2024542543A (ja)	2021-12-03	2024-11-15	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖウイルス感染症のための治療化合物
WO2024245157A1 (zh) *	2023-05-30	2024-12-05	浙江星浩澎博医药有限公司	氮杂喹啉环衍生物
WO2024249983A1 (en) *	2023-06-02	2024-12-05	Westol, Llc	2,8-dihydroxyquinoline glucuronide derivatives with enhanced properties for use as anticancer, antiviral, antimicrobial, and other therapeutic applications
WO2025020886A1 (zh) *	2023-07-27	2025-01-30	浙江星浩澎博医药有限公司	氮杂喹唑啉环衍生物及其用途
KR102732584B1 (ko)	2024-03-28	2024-11-21	(주)신한티이씨	전기 배전반의 화재 위험 감지 및 진압용 소화 장치

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3930837A (en)	1971-12-31	1976-01-06	Ici Australia Limited	3-chloro-5-acetamidaisoquinoline as a herbicide
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
IT7819093A0 (it)	1977-01-10	1978-01-06	Ciba Geigy	Prodotti antielmintici e loro impiego.
US4326525A (en)	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US5364620A (en)	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4902514A (en)	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
JP2634438B2 (ja)	1988-07-26	1997-07-23	三井東圧化学株式会社	不斉ビスオキサゾリルピリジン誘導体およびその製造方法
DE4014171A1 (de)	1990-05-03	1991-11-07	Basf Ag	Cyanochinolinverbindungen
GB9310700D0 (en)	1993-05-24	1993-07-07	Zeneca Ltd	Novel composition
UA73073C2 (uk) *	1997-04-03	2005-06-15	Уайт Холдінгз Корпорейшн	Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
WO1999011124A1 (fr)	1997-08-28	1999-03-11	Nissan Chemical Industries, Ltd.	Agents antibacteriens et antifongiques, algicides et agents antisalissure a base de cyanoacrylate, a usage industriel
DK1097158T3 (da)	1998-07-10	2006-05-29	Massachusetts Inst Technology	Ligander til metaller og metalkatalyserede metoder
PL218769B1 (pl)	1998-09-29	2015-01-30	Wyeth Corp	Podstawione 3-cyjanochinoliny lub ich farmaceutycznie dopuszczalne sole jako inhibitory białkowych kinaz tyrozynowych
US6930100B2 (en)	2002-03-20	2005-08-16	Bristol-Myers Squibb Company	Phosphate prodrugs of fluoroxindoles
JP2006515341A (ja)	2003-03-03	2006-05-25	エフ．ホフマン−ラ　ロシュ　アーゲー	５−ｈｔ６調節物質として使用するための２，５−および２，６−置換テトラヒドロイソキノリン
CN1835923A (zh)	2003-08-19	2006-09-20	惠氏控股公司	制备4－氨基－3－喹啉腈的方法
US7399865B2 (en)	2003-09-15	2008-07-15	Wyeth	Protein tyrosine kinase enzyme inhibitors
TW200529846A (en) *	2004-02-20	2005-09-16	Wyeth Corp	3-quinolinecarbonitrile protein kinase inhibitors
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
CA2608540A1 (en)	2005-05-18	2006-11-23	Wyeth	3-cyanoquinoline inhibitors of tpl2 kinase and methods of making and using the same
CN101223170A (zh) *	2005-05-18	2008-07-16	惠氏公司	Tpl2激酶的4,6-二氨基-[1,7]萘啶-3-甲腈抑制剂以及其制备和使用方法
KR20080067361A (ko)	2005-10-28	2008-07-18	아보트 러보러터리즈	Ｔｒｐｖ1 수용체를 억제하는 인다졸 유도체
MX2008012482A (es)	2006-03-31	2008-10-10	Abbott Lab	Compuestos de indazol.
EP2086960B1 (en)	2006-11-09	2014-03-05	Probiodrug AG	Novel inhibitors of glutaminyl cyclase
US8389544B2 (en)	2007-01-17	2013-03-05	The Hong Kong University Of Science And Technology	Isoquinolone compounds as subtype-selective agonists for melatonin receptors MT1 and MT2
GB0820856D0 (en)	2008-11-14	2008-12-24	Univ Leuven Kath	Novel inhibitors of flavivirus replication
TWI598347B (zh)	2009-07-13	2017-09-11	基利科學股份有限公司	調節細胞凋亡信號之激酶的抑制劑
GB0922302D0 (en) *	2009-12-22	2010-02-03	Imp Innovations Ltd	Compounds
MX343368B (es)	2010-03-09	2016-11-01	The Broad Inst Inc *	Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
EP3222620B1 (en)	2010-06-09	2019-11-20	Tianjin Hemay Oncology Pharmaceutical Co., Ltd.	Cyanoquinoline derivatives
US9453021B2 (en)	2011-05-10	2016-09-27	Kyowa Hakko Kirin Co., Ltd.	Pyrimidodiazepinone compound
EP2729007A1 (de)	2011-07-04	2014-05-14	Bayer Intellectual Property GmbH	Verwendung substituierter isochinolinone, isochinolindione, isochinolintrione und dihydroisochinolinone oder jeweils deren salze als wirkstoffe gegen abiotischen pflanzenstress
EP2545964A1 (en)	2011-07-13	2013-01-16	Phenex Pharmaceuticals AG	Novel FXR (NR1H4) binding and activity modulating compounds
PH12014500921A1 (en)	2011-10-27	2014-06-09	Taisho Pharmaceutical Co Ltd	Azole derivative
SMT201800191T1 (it)	2011-11-11	2018-05-02	Gilead Apollo Llc	Inibitori di acc e loro usi
UY34573A (es)	2012-01-27	2013-06-28	Gilead Sciences Inc	Inhibidor de la quinasa que regula la señal de la apoptosis
CN103483363B (zh)	2012-06-13	2016-12-21	上海赛迦化工产品有限公司	多样性的手性氨基硼酸及其制备方法和应用
US20150297573A1 (en)	2012-10-24	2015-10-22	INSERM (Institut National de la Santé et de la Recherche Médicale)	TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
CN103408572B (zh)	2013-07-12	2015-12-02	上海工程技术大学	手性氨基硼酸衍生物及其制备方法和应用
JP6542794B2 (ja)	2013-12-12	2019-07-10	ゼノロイアルティーアンドマイルストーンズリミテッドライアビリティーカンパニー	二環式アルキル化合物、および合成
EP3114107B1 (en)	2014-03-07	2020-07-22	Recurium IP Holdings, LLC	Propellane derivates and synthesis
US9701661B2 (en) *	2014-07-11	2017-07-11	Northwestern University	2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase
KR20170048588A (ko)	2014-09-17	2017-05-08	카리라 파마슈티컬스, 아이앤씨.	바이사이클릭 화합물
CA2962572A1 (en)	2014-09-24	2016-03-31	Gilead Sciences, Inc.	Methods of treating liver disease with a combination of an ask1 inhibitor and a fxr agonist
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
AU2015369668B2 (en)	2014-12-23	2019-04-18	Gilead Sciences, Inc.	Processes for preparing ASK1 inhibitors
AU2016205138A1 (en)	2015-01-09	2017-07-13	Gilead Apollo, Llc	ACC inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease
KR102205143B1 (ko)	2015-01-16	2021-01-21	쓰리엠 이노베이티브 프로퍼티즈 컴파니	그리드 결과를 개선하기 위해 그리드 액션을 선택하기 위한 시스템 및 방법
UA123010C2 (uk)	2015-07-06	2021-02-03	Гіліад Сайєнсіз, Інк.	Модулятори сот та способи їх застосування
US9815818B2 (en) *	2015-07-06	2017-11-14	Gilead Sciences, Inc.	Cot modulators and methods of use thereof
EP3398598B1 (en)	2015-12-31	2022-04-06	Hitgen Inc.	Sulfonamide derivative and preparation method and use thereof
CN108699078A (zh)	2016-03-02	2018-10-23	吉利德阿波罗公司	噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
WO2017221944A1 (ja)	2016-06-21	2017-12-28	パナソニックヘルスケアホールディングス株式会社	カタラーゼ阻害剤及びカタラーゼ阻害剤を用いるアナライトの測定方法
EP3478674B1 (en)	2016-06-30	2020-05-13	Gilead Sciences, Inc.	4,6-diaminoquinazolines as cot modulators and methods of use thereof
CN106512014A (zh)	2016-10-27	2017-03-22	武汉大学	肿瘤进展位点2在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
KR102485620B1 (ko)	2017-03-03	2023-01-09	길리애드 사이언시즈, 인코포레이티드	Acc 억제제 및 그의 고체 형태를 제조하는 방법
KR20220119520A (ko)	2017-03-28	2022-08-29	길리애드 사이언시즈, 인코포레이티드	간 질환을 치료하기 위한 치료 조합물
CN110520125A (zh)	2017-04-12	2019-11-29	吉利德科学公司	治疗肝病的方法
CA3077273A1 (en)	2017-10-06	2019-04-11	Gilead Sciences, Inc.	Combination therapy comprising an acc inhibitor
CN118388474A (zh)	2019-02-19	2024-07-26	吉利德科学公司	Fxr激动剂的固体形式
EP3934615A4 (en)	2019-03-08	2023-01-25	The Regents Of The University Of California	ACNE TREATMENT COMPOSITIONS AND METHODS
TW202235416A (zh)	2019-06-14	2022-09-16	美商基利科學股份有限公司	Cot 調節劑及其使用方法
AR119594A1 (es)	2019-08-09	2021-12-29	Gilead Sciences Inc	Derivados de tienopirimidina como inhibidores acc y usos de los mismos
JP2023520650A (ja)	2020-03-30	2023-05-18	ギリアードサイエンシーズ，インコーポレイテッド	（Ｓ）－６－（（（１－（ビシクロ［１．１．１］ペンタン－１－イル）－１Ｈ－１，２，３－トリアゾール－４－イル）２－メチル－１－オキソ－１，２－ジヒドロイソキノリン－５－イル）メチル）））アミノ）８－クロロ－（ネオペンチルアミノ）キノリン－３－カルボニトリルＣｏｔ阻害剤化合物の固体形態
CN119390681A (zh)	2020-04-02	2025-02-07	吉利德科学公司	用于制备cot抑制剂化合物的方法
TW202345826A (zh)	2021-06-04	2023-12-01	美商基利科學股份有限公司	治療nash之方法

2016
- 2016-06-30 UA UAA201712984A patent/UA123010C2/uk unknown
- 2016-06-30 CN CN202210008753.1A patent/CN114380799B/zh active Active
- 2016-06-30 ME MEP-2019-117A patent/ME03425B/me unknown
- 2016-06-30 MA MA39422A patent/MA39422B1/fr unknown
- 2016-06-30 ES ES16738976T patent/ES2734713T3/es active Active
- 2016-06-30 CU CUP2017000172A patent/CU20170172A7/xx unknown
- 2016-06-30 NZ NZ738525A patent/NZ738525A/en unknown
- 2016-06-30 PT PT16738976T patent/PT3191470T/pt unknown
- 2016-06-30 WO PCT/US2016/040520 patent/WO2017007689A1/en active Application Filing
- 2016-06-30 CN CN202411260421.8A patent/CN119143730A/zh active Pending
- 2016-06-30 KR KR1020227031078A patent/KR20220129667A/ko not_active Ceased
- 2016-06-30 CN CN201910292757.5A patent/CN109879859B/zh active Active
- 2016-06-30 EP EP21162393.9A patent/EP3896064A1/en active Pending
- 2016-06-30 RS RS20190498A patent/RS58639B1/sr unknown
- 2016-06-30 EP EP16738976.6A patent/EP3191470B1/en active Active
- 2016-06-30 MX MX2017004737A patent/MX370984B/es active IP Right Grant
- 2016-06-30 KR KR1020207002878A patent/KR102443575B1/ko active Active
- 2016-06-30 EP EP18186568.4A patent/EP3456717B1/en active Active
- 2016-06-30 PT PT181865684T patent/PT3456717T/pt unknown
- 2016-06-30 AU AU2016290820A patent/AU2016290820B2/en active Active
- 2016-06-30 CR CR20170599A patent/CR20170599A/es unknown
- 2016-06-30 US US15/199,534 patent/US20170008905A1/en not_active Abandoned
- 2016-06-30 KR KR1020247000058A patent/KR20240008398A/ko not_active Ceased
- 2016-06-30 IL IL293770A patent/IL293770B2/en unknown
- 2016-06-30 PL PL16738976T patent/PL3191470T3/pl unknown
- 2016-06-30 CN CN201680050602.5A patent/CN107922390B/zh active Active
- 2016-06-30 LT LTEP16738976.6T patent/LT3191470T/lt unknown
- 2016-06-30 SI SI201631197T patent/SI3456717T1/sl unknown
- 2016-06-30 PE PE2017002804A patent/PE20180462A1/es unknown
- 2016-06-30 JP JP2018500585A patent/JP6430060B2/ja active Active
- 2016-06-30 KR KR1020197011792A patent/KR102073641B1/ko active Active
- 2016-06-30 SG SG11201702041PA patent/SG11201702041PA/en unknown
- 2016-06-30 ES ES18186568T patent/ES2872076T3/es active Active
- 2016-06-30 SM SM20190244T patent/SMT201900244T1/it unknown
- 2016-06-30 HU HUE16738976A patent/HUE043310T2/hu unknown
- 2016-06-30 NZ NZ750707A patent/NZ750707A/en unknown
- 2016-06-30 KR KR1020187003221A patent/KR101974793B1/ko active Active
- 2016-06-30 MY MYPI2018700007A patent/MY196173A/en unknown
- 2016-06-30 EA EA201792613A patent/EA036788B1/ru unknown
- 2016-06-30 IL IL274568A patent/IL274568B/en unknown
- 2016-06-30 DK DK16738976.6T patent/DK3191470T3/en active
- 2016-06-30 CA CA2971640A patent/CA2971640C/en active Active
- 2016-06-30 SI SI201630202T patent/SI3191470T1/sl unknown
- 2016-06-30 PL PL18186568T patent/PL3456717T3/pl unknown
- 2016-07-04 BR BR102016015656-4A patent/BR102016015656B1/pt active IP Right Grant
- 2016-07-05 TW TW109122003A patent/TWI748539B/zh active
- 2016-07-05 TW TW105121281A patent/TWI634112B/zh active
- 2016-07-05 TW TW107117905A patent/TWI699361B/zh active
- 2016-07-06 UY UY0001036771A patent/UY36771A/es not_active Application Discontinuation
2017
- 2017-02-09 US US15/429,086 patent/US9878995B2/en active Active
- 2017-04-18 SA SA517381350A patent/SA517381350B1/ar unknown
- 2017-12-20 IL IL256433A patent/IL256433B/en active IP Right Grant
- 2017-12-22 EC ECIEPI201784635A patent/ECSP17084635A/es unknown
- 2017-12-22 CL CL2017003356A patent/CL2017003356A1/es unknown
- 2017-12-22 CO CONC2017/0013351A patent/CO2017013351A2/es unknown
- 2017-12-22 SV SV2017005605A patent/SV2017005605A/es unknown
- 2017-12-26 DO DO2017000311A patent/DOP2017000311A/es unknown
2018
- 2018-01-03 PH PH12018500031A patent/PH12018500031B1/en unknown
- 2018-02-07 US US15/891,163 patent/US20180237455A1/en not_active Abandoned
- 2018-09-13 JP JP2018171794A patent/JP6781221B2/ja active Active
2019
- 2019-04-23 US US16/391,673 patent/US20190248807A1/en not_active Abandoned
- 2019-05-03 AU AU2019203122A patent/AU2019203122B2/en active Active
- 2019-05-08 HR HRP20190853TT patent/HRP20190853T1/hr unknown
- 2019-05-20 CY CY20191100535T patent/CY1121750T1/el unknown
- 2019-05-29 IL IL266995A patent/IL266995B/en active IP Right Grant
- 2019-07-26 JP JP2019137759A patent/JP6906021B2/ja active Active
- 2019-12-17 US US16/717,074 patent/US11066414B2/en active Active
2020
- 2020-09-06 PH PH12020551397A patent/PH12020551397A1/en unknown
- 2020-10-20 AU AU2020257055A patent/AU2020257055B2/en active Active
- 2020-12-16 JP JP2020208330A patent/JP7138155B2/ja active Active
2021
- 2021-05-11 US US17/317,041 patent/US11905299B2/en active Active
2022
- 2022-04-11 JP JP2022065168A patent/JP2022082816A/ja not_active Withdrawn
- 2022-06-10 AU AU2022204050A patent/AU2022204050B2/en active Active
2023
- 2023-12-11 US US18/534,800 patent/US20240254137A1/en active Pending
2024
- 2024-05-17 JP JP2024081151A patent/JP2024100865A/ja active Pending
- 2024-07-17 AU AU2024204902A patent/AU2024204902A1/en not_active Abandoned

Also Published As

Publication number	Publication date
IL274568B (en)	2022-07-01
IL293770A (en)	2022-08-01
US20230002407A1 (en)	2023-01-05
MY196173A (en)	2023-03-17
WO2017007689A1 (en)	2017-01-12
TWI748539B (zh)	2021-12-01
SI3456717T1 (sl)	2021-08-31
IL293770B2 (en)	2023-07-01
IL274568A (en)	2020-06-30
SI3191470T1 (sl)	2019-04-30
TWI634112B (zh)	2018-09-01
MA39422A (fr)	2017-07-19
PE20180462A1 (es)	2018-03-06
KR20180022982A (ko)	2018-03-06
US11066414B2 (en)	2021-07-20
SV2017005605A (es)	2018-07-18
EP3896064A1 (en)	2021-10-20
PT3191470T (pt)	2019-06-05
KR20200013120A (ko)	2020-02-05
KR20240008398A (ko)	2024-01-18
US20200123172A1 (en)	2020-04-23
US20170152240A1 (en)	2017-06-01
DOP2017000311A (es)	2018-01-15
BR102016015656A2 (pt)	2020-09-24
CN107922390B (zh)	2019-05-10
JP2022082816A (ja)	2022-06-02
CA2971640C (en)	2020-09-22
IL293770B1 (en)	2023-03-01
DK3191470T3 (en)	2019-04-15
AU2019203122A1 (en)	2019-05-30
CL2017003356A1 (es)	2018-07-06
AU2016290820B2 (en)	2019-03-07
US9878995B2 (en)	2018-01-30
PT3456717T (pt)	2021-05-26
TW202114673A (zh)	2021-04-16
KR20190045416A (ko)	2019-05-02
EA036788B1 (ru)	2020-12-21
TW201908305A (zh)	2019-03-01
PH12018500031A1 (en)	2018-07-09
UA123010C2 (uk)	2021-02-03
EP3456717A1 (en)	2019-03-20
BR102016015656B1 (pt)	2021-11-03
MA39422B1 (fr)	2019-03-29
ES2734713T3 (es)	2019-12-11
CA2971640A1 (en)	2017-01-12
AU2022204050A1 (en)	2022-06-30
IL256433B (en)	2019-06-30
ECSP17084635A (es)	2018-01-31
MX370984B (es)	2020-01-09
KR102073641B1 (ko)	2020-02-05
AU2022204050B2 (en)	2024-04-18
IL266995B (en)	2020-05-31
SG11201702041PA (en)	2017-04-27
PL3191470T3 (pl)	2019-08-30
CN114380799A (zh)	2022-04-22
CN119143730A (zh)	2024-12-17
PH12018500031B1 (en)	2018-07-09
IL256433A (en)	2018-02-28
PH12020551397A1 (en)	2021-08-16
EA201792613A1 (ru)	2018-06-29
JP2021042252A (ja)	2021-03-18
NZ738525A (en)	2019-03-29
JP7138155B2 (ja)	2022-09-15
AU2019203122B2 (en)	2020-10-01
EP3456717B1 (en)	2021-03-17
KR101974793B1 (ko)	2019-05-02
CN109879859B (zh)	2022-01-25
JP6430060B2 (ja)	2018-11-28
JP2018520161A (ja)	2018-07-26
TWI699361B (zh)	2020-07-21
EP3191470B1 (en)	2019-02-27
US11905299B2 (en)	2024-02-20
AU2020257055B2 (en)	2022-03-31
SMT201900244T1 (it)	2019-05-10
SA517381350B1 (ar)	2021-03-11
US20180237455A1 (en)	2018-08-23
EP3191470A1 (en)	2017-07-19
ME03425B (me)	2020-01-20
US20170008905A1 (en)	2017-01-12
UY36771A (es)	2017-01-31
LT3191470T (lt)	2019-05-10
JP2019178178A (ja)	2019-10-17
NZ750707A (en)	2023-09-29
CN114380799B (zh)	2024-10-01
AU2024204902A1 (en)	2024-08-01
KR20220129667A (ko)	2022-09-23
CN109879859A (zh)	2019-06-14
RS58639B1 (sr)	2019-05-31
IL266995A (en)	2019-07-31
AU2016290820A1 (en)	2018-01-18
ES2872076T3 (es)	2021-11-02
KR102443575B1 (ko)	2022-09-16
JP6906021B2 (ja)	2021-07-21
US20240254137A1 (en)	2024-08-01
CO2017013351A2 (es)	2018-05-21
PL3456717T3 (pl)	2021-10-25
CY1121750T1 (el)	2020-07-31
MX2017004737A (es)	2017-06-19
TW201712005A (zh)	2017-04-01
CR20170599A (es)	2018-02-28
JP6781221B2 (ja)	2020-11-04
CN107922390A (zh)	2018-04-17
US20190248807A1 (en)	2019-08-15
JP2018193405A (ja)	2018-12-06
AU2020257055A1 (en)	2020-11-12
HRP20190853T1 (hr)	2019-06-28
HUE043310T2 (hu)	2019-08-28
JP2024100865A (ja)	2024-07-26

Publication	Publication Date	Title
CU20170172A7 (es)	2018-06-05	4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
ECSP24031979A (es)	2024-06-28	Compuestos terapéuticamente activos y sus métodos de uso
CO2018006714A2 (es)	2018-07-10	3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
DOP2016000071A (es)	2016-09-15	Inhibidores de tirosina cinasa de bruton
CL2018002291A1 (es)	2018-09-14	Anticuerpos anti-fgfr2iiib afucosilados (divisional solicitud 201600221)
GT201400297A (es)	2017-08-24	Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
NI201500140A (es)	2015-11-24	Compuestos y composiciones terapéuticos
CO2018004857A2 (es)	2018-07-19	Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY35590A (es)	2014-11-28	Nuevos compuestos para el tratamiento del cáncer
GT201500312A (es)	2018-01-17	Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015002164A1 (es)	2016-06-17	Formulación combinada de dos compuesos antivirales.
CR20150228A (es)	2015-09-14	Inhibidores de la tirosina-quinasa de bruton
MX2016011810A (es)	2017-04-27	Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
UY35467A (es)	2014-10-31	Compuestos orgánicos
GT201700023A (es)	2019-06-10	Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2014001865A1 (es)	2015-06-26	Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
UY35276A (es)	2014-08-29	Nuevos compuestos que inhiben la actividad de Lp-PLA2
GT201500247A (es)	2017-10-05	Imidazopiridazinas sustituidas
DOP2018000062A (es)	2018-03-30	Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CL2016001587A1 (es)	2016-12-02	Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
MX2015012833A (es)	2016-06-10	Composiciones antibioticas de ceftolozano.
NI201500096A (es)	2016-02-16	Compuesto químicos
SV2018005760A (es)	2019-03-08	Derivados de aminotiazol utiles como agentes antiviricos
CU20150061A7 (es)	2015-12-23	PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO
SV2017005466A (es)	2018-10-02	Pirazolpiridinaminas como inhibidores de mknk1 y mknk2